Models of Screening, Brief Intervention With a Facilitated Referral to Treatment (SBIRT) for Opioid Patients in the Emergency Department
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00913770 |
Recruitment Status :
Completed
First Posted : June 4, 2009
Results First Posted : May 28, 2015
Last Update Posted : March 24, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Opiate Addiction | Behavioral: Brief Negotiation Interview (BNI) Drug: Buprenorphine Initiation | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 329 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Models of Screening, Brief Intervention With a Facilitated Referral to Treatment (SBIRT) for Opioid Patients in the Emergency Department |
Study Start Date : | September 2008 |
Actual Primary Completion Date : | August 2013 |
Actual Study Completion Date : | December 2014 |

Arm | Intervention/treatment |
---|---|
No Intervention: SC
Standard Care
|
|
Experimental: SBIRT
Screening, Brief Intervention and Facilitated Referral to Treatment
|
Behavioral: Brief Negotiation Interview (BNI)
Brief Negotiation Interview (BNI) is a manual-guided therapy that is designed to be feasible in the ED setting. The purpose of the BNI is to assist patients in recognizing and changing their drug use and HIV risk behaviors. It combines techniques based on motivational interviewing and a stage-model of change. The main goal of the interview is to decrease the subject's ambivalence about signing up for a formal drug treatment program. |
Experimental: SBI+Bup
Screening, Brief Intervention and Buprenorphine initiation
|
Behavioral: Brief Negotiation Interview (BNI)
Brief Negotiation Interview (BNI) is a manual-guided therapy that is designed to be feasible in the ED setting. The purpose of the BNI is to assist patients in recognizing and changing their drug use and HIV risk behaviors. It combines techniques based on motivational interviewing and a stage-model of change. The main goal of the interview is to decrease the subject's ambivalence about signing up for a formal drug treatment program. Drug: Buprenorphine Initiation |
- Self-reported Engagement in Formal Substance Abuse Treatment at 30 Days (Verified by Contact With the Treatment Program) [ Time Frame: 30 days post randomization ]Defined as enrollment and receiving formal addiction treatment on the 30th day following randomization. This is assessed by direct contact with facility, clinician, or both.
- Days of Self-reported Illicit Opioid Use in the Past 7 Days [ Time Frame: 30 days post randomization ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Patients who present to the adult ED at Yale-New Haven Hospital (YNHH) who are:
- 18 years or older,
- meet criteria for opioid dependence as measured by the Mini-SCID, and
- have a positive urine toxicology for opiates.
Exclusion Criteria:
- Inability to read or understand English
- Currently receiving formal substance abuse treatment
- Current suicide or homicidal risk
- Current psychotic disorder
- Life-threatening or unstable medical or psychiatric condition requiring hospital admission
- Unable to provide 2 phone contact numbers
- Unwilling to be randomized and/or follow up as per study protocol, including release of information to assess treatment engagement at 30-days
- Requiring opioid agonist medication for a pain-related diagnosis (contraindication to buprenorphine)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00913770
United States, Connecticut | |
Yale University | |
New Haven, Connecticut, United States, 06510 | |
Yale University School of Medicine | |
New Haven, Connecticut, United States, 06519 |
Principal Investigator: | Gail D'Onofrio, MD, MS | Yale University |
Responsible Party: | Yale University |
ClinicalTrials.gov Identifier: | NCT00913770 |
Other Study ID Numbers: |
0808004132 1R01DA025991-01 ( U.S. NIH Grant/Contract ) |
First Posted: | June 4, 2009 Key Record Dates |
Results First Posted: | May 28, 2015 |
Last Update Posted: | March 24, 2020 |
Last Verified: | March 2020 |
opioid dependence buprenorphine brief intervention |
Emergencies Opioid-Related Disorders Disease Attributes Pathologic Processes Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Buprenorphine |
Analgesics, Opioid Narcotics Central Nervous System Depressants Physiological Effects of Drugs Analgesics Sensory System Agents Peripheral Nervous System Agents Narcotic Antagonists |